Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma

Liu, Chang; Li, Nan; Lü, Hongyan; Wang, Zhengkai; Chen, Chunyan; Wu, Lin; Liu, Jiong; Lu, Youke; Wang, Fangyu

doi:10.3892/br.2014.388

Cited by 15 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we confirmed that in breast cancer the downregulation of SFRP1 associated with promoter methylation. Several groups have proposed the use of SFRP1 promoter methylation as a cancer biomarker, and our study provides further support for this concept 20 21 22 23 24 .…”

Section: Discussionsupporting

confidence: 80%

A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function

Vincent

Postovit

2017

Sci Rep

View full text Add to dashboard Cite

Secreted frizzled-related proteins (SFRPs), containing five family members (SFRPs 1–5) are putative extracellular Wnt inhibitors. Given their abilities to inhibit Wnt signalling, as well as the loss of SFRP1 in many cancers, this family is generally considered to be tumour suppressive. In this study we analyzed gene expression, promoter methylation and survival data from over 8000 tumour and normal samples from 29 cancers in order to map the context-specific associations of SFRPs 1–5 with patient survival, gene silencing and gene expression signatures. We show that only SFRP1 associates consistently with tumour suppressive functions, and that SFRP2 and SFRP4 typically associate with a poor prognosis concomitant with the expression of genes associated with epithelial-to-mesenchymal transition. Moreover, our results indicate that while SFRP1 is lost in cancer cells via the process of DNA methylation, SFRP2 and 4 are likely derived from the tumour stroma, and thus tend to increase in tumours as compared to normal tissues. This in-depth analysis highlights the need to study each SFRP as a separate entity and suggests that SFRP2 and SFRP4 should be approached as complex matricellular proteins with functions that extend far beyond their putative Wnt antagonistic ability.

show abstract

Section: Discussionsupporting

confidence: 80%

A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function

Vincent

Postovit

2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, of these 83 articles, 24 articles focused on CRC (4,5,9,30–35,72–85,93), 4 on leukemia (13,55–57), 4 on lung cancer (58,59,61,68), 8 on HCC (8,49–54,88), 6 on esophageal cancer (EC) (37–42,87), 9 on gastric cancer (GC) (5,39,43–47,84,92), 5 on BC (3,18,19,28), 4 on renal cell carcinoma (RCC) (68–71) and the remaining 21 on other types of cancer. A single article evaluated SFRP methylation levels in esophageal cancer and GC (39), and 1 article evaluated SFRP methylation levels in GC and CRC (5). The information on SFRP1, SFRP2, SFRP4 and SFRP5 methylation was collected from eligible studies and presented in Table SI.…”

Section: Resultsmentioning

confidence: 99%

Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta‑analysis

Xie

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Abnormal methylation of secreted frizzled-related proteins (SFRPs) has been observed in various human cancer types. The loss of SFRP gene expression induces the activation of the Wnt pathway and is a vital mechanism for tumorigenesis and development. The aim of the present systematic review was to assess the association between SFRP methylation and cancer risk. A meta-analysis was systematically conducted to assess the clinicopathological significance of SFRP methylation in cancer risk. The Cochrane Library, PubMed and Web of Science databases were comprehensively searched, and 83 publications with a total of 21,612 samples were selected for the meta-analysis. The pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated to evaluate the degree of associations between SFRP promoter methylation and cancer risk. Subgroup analysis, meta regression and sensitivity analysis were used to identify the potential sources of heterogeneity. SFRP1, SFRP2, SFRP4 and SFRP5 hypermethylation was significantly associated with cancer risk, with ORs of 8.48 (95% CI, 6.26–11.49), 8.21 (95% CI, 6.20–10.88), 11.41 (95% CI, 6.42–20.30) and 6.34 (95% CI, 3.86–10.42), respectively. SFRP2 methylation was significantly associated with differentiation in colorectal cancer (OR, 2.16; 95% CI, 1.02–4.56). The results of the present study demonstrated that SFRP methylation may contribute to carcinogenesis, especially in certain cancer types, including hepatocellular carcinoma and colorectal cancer.

show abstract

“…Such methylation events include hypermethylation of genes SFRP1, CASZ1, CDH13, ING2, DKK-3, TAC1, etc. (45)(46)(47)82).…”

Section: Clinical Implications Of Dna Methylation Change In Esccmentioning

confidence: 99%

Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications

Lin

Xu²,

Ding

2020

Front. Oncol.

View full text Add to dashboard Cite

Almost all cancer cells possess multiple epigenetic abnormalities, which cooperate with genetic alterations to enable the acquisition of cancer hallmarks during tumorigenesis. As the most frequently found epigenetic change in human cancers, aberrant DNA methylation manifests at two major forms: global genomic DNA hypomethylation and locus-specific promoter region hypermethylation. It has been recognized as a critical contributor to esophageal squamous cell carcinoma (ESCC) malignant transformation. In ESCC, DNA methylation alterations affect genes involved in cell cycle regulation, DNA damage repair, and cancer-related signaling pathways. Aberrant DNA methylation patterns occur not only in ESCC tumors but also in precursor lesions. It adds another layer of complexity to the ESCC heterogeneity and may serve as early diagnostic, prognostic, and chemo-sensitive markers. Characterization of the DNA methylome in ESCC could help better understand its pathogenesis and develop improved therapies. We herein summarize the current research and knowledge about DNA methylation in ESCC and its clinical significance in diagnosis, prognosis, and treatment.

show abstract

Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma

Cited by 15 publications

References 22 publications

A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function

A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function

Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta‑analysis

Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications

Contact Info

Product

Resources

About